By Counterforce Health Team in Blenrep (belantamab mafodotin) —

Renewing Blenrep (Belantamab Mafodotin) Approval with UnitedHealthcare in Pennsylvania: Timeline, Documents & Appeal Process

Quick Answer: Blenrep Renewal with UnitedHealthcare in Pennsylvania

Current Status: Blenrep (belantamab mafodotin) was withdrawn from the U.S. market in 2022 and is only available through clinical trials or expanded access programs. UnitedHealthcare typically denies coverage outside these settings. For trial-related bridge therapy or expanded access, submit prior authorization 30 days before current approval expires. If denied, Pennsylvania's external review program has a 53% overturn rate. First step: Contact your oncologist to verify current access pathway and gather clinical documentation.

Table of Contents

Understanding Blenrep's Current Status

Blenrep (belantamab mafodotin) is an anti-BCMA antibody-drug conjugate manufactured by GSK that was voluntarily withdrawn from the U.S. market in November 2022 due to efficacy concerns. The drug is currently under FDA review with a PDUFA date of October 23, 2025, but remains unavailable for commercial use.

Current Access Pathways:

  • Clinical trials for multiple myeloma patients
  • Expanded access programs (compassionate use)
  • International procurement (not covered by U.S. insurance)

UnitedHealthcare's OptumRx typically denies coverage for withdrawn medications unless they're part of an approved clinical trial or expanded access program with proper documentation.

Note: Even if Blenrep returns to market in late 2025, it will require new prior authorization submissions and REMS program enrollment due to ocular toxicity monitoring requirements.

Renewal Triggers and Timing Windows

When to Start Renewal Process

For Clinical Trial Participants:

  • 90 days before trial completion if transitioning to commercial access
  • 60 days before expanded access authorization expires
  • 30 days before bridge therapy approval ends

UnitedHealthcare OptumRx Timeline: OptumRx requires annual reauthorization for most specialty oncology drugs, with specific timelines varying by medication. Submit renewal requests before current authorization expires to avoid treatment interruptions.

Early Warning Signs

  • Denial letter stating "investigational use only"
  • Pharmacy rejection at fill attempt
  • Prior authorization expiration notice from OptumRx
  • Clinical trial coordinator notification of study completion

Evidence Update Requirements

Clinical Response Documentation

Your oncologist must provide updated evidence of:

Treatment Response:

  • Recent M-protein levels or light chain measurements
  • Bone marrow biopsy results (if applicable)
  • Imaging studies showing disease status
  • Performance status assessment

Safety Monitoring:

  • Ophthalmologic examinations (required for Blenrep REMS)
  • Complete blood counts and chemistry panels
  • Documentation of manageable adverse events
  • Adherence to monitoring protocols

Medical Necessity Justification:

  • Failure or intolerance to standard multiple myeloma therapies
  • Contraindications to BCMA-targeted alternatives (CAR-T, bispecifics)
  • Clinical rationale for continued treatment
Clinician Corner: Include specific NCCN guideline references and document why standard options like lenalidomide combinations, daratumumab regimens, or CAR-T therapy are inappropriate for this patient.

Building Your Renewal Packet

Required Documents Checklist

Clinical Documentation:

  • Updated letter of medical necessity from oncologist
  • Recent progress notes (last 3 months)
  • Laboratory results showing treatment response
  • REMS compliance documentation
  • Prior therapy failure documentation

Insurance Forms:

Supporting Evidence:

  • Clinical trial protocol (if applicable)
  • Expanded access program approval letter
  • Pharmacy benefit verification
  • Appeals history (if previously denied)

Letter of Medical Necessity Structure

Your oncologist should include:

  1. Patient diagnosis with ICD-10 codes (C90.00-C90.02 for multiple myeloma)
  2. Prior treatment history with specific dates and outcomes
  3. Current clinical status with objective measures
  4. Medical necessity rationale citing guidelines
  5. Monitoring plan including REMS compliance
  6. Treatment goals and expected duration

Submission Timeline and Decision Windows

UnitedHealthcare Processing Times

Standard Review: 15 business days from complete submission Expedited Review: 72 hours for urgent medical situations Incomplete Submissions: Additional 14 days after missing information provided

Submission Methods

Provider Portal: UnitedHealthcare Provider Portal - "Specialty Pharmacy Transactions" tile Fax: Check current fax number on denial letter or provider portal Phone: OptumRx Provider Support at 1-800-711-4555

Tip: Use the provider portal for real-time tracking and faster processing. The system shows submission status and any missing documentation requirements.

When Coverage Lapses: Bridge Options

Immediate Steps if Authorization Expires

  1. Contact your oncologist to discuss temporary alternatives
  2. Request expedited review if treatment interruption poses health risks
  3. Explore manufacturer assistance programs
  4. Consider clinical trial enrollment for continued access

Bridge Therapy Considerations

Since Blenrep isn't commercially available, bridge therapy typically involves:

  • Standard multiple myeloma regimens (covered by UnitedHealthcare)
  • Supportive care to maintain disease stability
  • Alternative BCMA-targeted therapies if available

Coverage Note: UnitedHealthcare covers routine care during clinical trials in Pennsylvania but not investigational drugs themselves, per Pennsylvania state regulations.

Annual Changes to Monitor

UnitedHealthcare Formulary Updates

UnitedHealthcare updates its formulary up to three times annually, not just during annual enrollment. Monitor for:

Specialty Tier Changes:

  • Movement between formulary tiers
  • New prior authorization requirements
  • Quantity limit modifications
  • Preferred pharmacy network changes

Policy Updates:

  • REMS program requirement changes
  • Step therapy protocol modifications
  • Medical exception criteria updates
  • Appeals process revisions

What to Re-verify Annually

  • Current formulary status and tier placement
  • Prior authorization criteria updates
  • Specialty pharmacy network requirements
  • Copayment and coinsurance amounts

Appeals Process in Pennsylvania

Pennsylvania's External Review Success

Pennsylvania's Independent External Review Program launched in January 2024 has overturned 53% of appealed denials in its first six months, including specialty drug cases.

Step-by-Step Appeals Process

Step 1: Internal Appeal with UnitedHealthcare

  • Submit within 180 days of denial
  • Include all clinical documentation
  • Request expedited review if medically urgent
  • Await Final Adverse Benefit Determination letter

Step 2: Pennsylvania External Review

  • File within 4 months of final denial
  • Submit online at pa.gov/reviewmyclaim
  • Call 1-877-881-6388 for assistance
  • Provide additional documentation within 15 days of assignment

Step 3: Decision and Implementation

  • Standard review: 45 days maximum
  • Expedited review: 72 hours for urgent cases
  • Binding decision on UnitedHealthcare
  • Immediate coverage if overturned
From Our Advocates: One Pennsylvania patient successfully appealed a specialty drug denial by submitting detailed treatment failure documentation and current clinical guidelines. The external reviewer agreed that standard therapies were inadequate, leading to coverage approval. While outcomes vary, thorough documentation significantly improves appeal success rates.

Personal Renewal Tracker

Key Dates to Log

Authorization Information:

  • Current approval start date: ___________
  • Current approval end date: ___________
  • Next renewal due date: ___________
  • OptumRx case number: ___________

Clinical Appointments:

  • Last oncology visit: ___________
  • Next scheduled visit: ___________
  • Recent lab work date: ___________
  • Eye exam date (REMS): ___________

Submission Tracking:

  • Renewal packet sent: ___________
  • UnitedHealthcare decision received: ___________
  • Appeal filed (if needed): ___________
  • External review requested: ___________

Monthly Action Items

  • Check UnitedHealthcare member portal for updates
  • Verify specialty pharmacy network status
  • Review upcoming appointment schedule
  • Monitor for formulary change notifications

Counterforce Health: Expert Appeals Support

When facing complex prior authorization renewals or denials, Counterforce Health specializes in turning insurance denials into successful appeals. The platform analyzes denial letters, payer policies, and clinical documentation to create targeted, evidence-backed appeals that align with each insurer's specific requirements. For challenging cases involving withdrawn drugs like Blenrep or complex clinical trial situations, professional appeals support can significantly improve approval odds while reducing the administrative burden on patients and providers.

FAQ: Common Renewal Questions

Q: How long does UnitedHealthcare PA renewal take in Pennsylvania? A: Standard renewals take up to 15 business days. Expedited reviews for urgent medical situations are completed within 72 hours.

Q: What if Blenrep becomes available again before my renewal? A: You'll need a new prior authorization submission, as withdrawn drugs require fresh approval when returning to market, including new REMS enrollment.

Q: Can I request an expedited appeal in Pennsylvania? A: Yes, both UnitedHealthcare internal appeals and Pennsylvania external reviews offer expedited processing for urgent medical situations.

Q: Does step therapy apply if I've already been on Blenrep? A: Typically no, but UnitedHealthcare may require documentation of why you cannot use currently available BCMA-targeted therapies.

Q: What happens if my clinical trial ends? A: Work with your oncologist 90 days before trial completion to explore commercial access options or alternative trial enrollment.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Coverage decisions depend on individual circumstances, plan specifics, and current policies. Always consult with your healthcare provider and insurance representative for personalized guidance. For additional help with insurance appeals in Pennsylvania, contact the Pennsylvania Insurance Department Consumer Services at 1-877-881-6388.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.